Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 See also  




2 References  













ADB-P7AICA






●中文
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

ADB-P7AICA
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class B
    • Identifiers

    • N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-pentylpyrrolo[2,3-b]pyridine-3-carboxamide

    CAS Number
    PubChem CID
    ChemSpider
    CompTox Dashboard (EPA)
    Chemical and physical data
    FormulaC19H28N4O2
    Molar mass344.459 g·mol−1
    3D model (JSmol)

    • NC(=O)[C@@H](NC(=O)c1cn(CCCCC)c2ncccc21)C(C)(C)C

    • InChI=1S/C19H28N4O2/c1-5-6-7-11-23-12-14(13-9-8-10-21-17(13)23)18(25)22-15(16(20)24)19(2,3)4/h8-10,12,15H,5-7,11H2,1-4H3,(H2,20,24)(H,22,25)/t15-/m1/s1

    • Key:QDZHLYBDQFZWCJ-OAHLLOKOSA-N

    ADB-P7AICA is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products, first identified by the DEA in early 2021.[1][2]

    See also

    [edit]

    References

    [edit]
    1. ^ "Announcement of a Newly Identified Synthetic Cannabinoid ADB-P7AICA" (PDF). Drug Enforcement Administration Toxicology Testing Program. U.S. Department of Justice. 22 February 2021.
  • ^ Sparkes E, Cairns EA, Kevin RC, Lai F, Grafinger KE, Chen S, et al. (February 2022). "Structure-activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA". RSC Medicinal Chemistry. 13 (2): 156–174. doi:10.1039/d1md00242b. PMC 8864554. PMID 35308023.

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=ADB-P7AICA&oldid=1194066549"
    Categories: 
    ●Cannabinoids
     ●Designer drugs
     ●Pyrrolopyridines
     ●Tert-butyl compounds
     Hidden categories: 
    ●Articles with short description
     ●Short description is different from Wikidata
     ●Articles without EBI source
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Articles without UNII source
     ●Drugs missing an ATC code
     ●Articles containing unverified chemical infoboxes
      


    ●This page was last edited on 7 January 2024, at 01:26 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki